Tesamorelin – COMPREHENSIVE RESEARCH PEPTIDE FOR GROWTH HORMONE RELEASING HORMONE ANALOG AND METABOLIC REGULATION STUDIES

Scientific Overview of Tesamorelin

Tesamorelin, also known as TH9507, is a synthetic analog of human growth hormone–releasing hormone (GHRH) with enhanced stability and receptor affinity. It incorporates a trans-3-hexenoic acid modification at the N-terminus, extending its biological half-life and making it a powerful tool for studies of endocrine signaling, growth hormone regulation, and lipid metabolism.

In in-vitro and in-vivo research, Tesamorelin has been investigated for its role in:

• GHRH Receptor Activation and Signal Transduction – analysis of peptide–receptor interactions and cyclic AMP (cAMP)-mediated GH secretion pathways (Corpas et al., 1993)
• Endocrine and Metabolic Effects – evaluation of GH–IGF-1 axis modulation and downstream effects on lipolysis, glucose metabolism, and insulin sensitivity (Feldt-Rasmussen et al., 2011)
• Molecular Stability and Pharmacokinetics – investigation of Tesamorelin’s enhanced resistance to enzymatic degradation and prolonged receptor activation (Peroni et al., 2013)

Tesamorelin serves as a valuable model peptide for exploring GHRH receptor pharmacodynamics, metabolic regulation, and peptide optimization for endocrine modulation. Its unique design offers insights into growth hormone biology, metabolic homeostasis, and therapeutic analog development.